Core Insights - Bio-Techne Corporation has announced a partnership with MedSanTek to distribute its brands in Turkey, enhancing its market presence in the region [1][3] - MedSanTek is recognized as a leading distributor in in vitro diagnostics and research products, serving Turkey and Azerbaijan, and is known for its high-quality solutions in various scientific fields [2][3] - The partnership aims to leverage MedSanTek's local expertise and Bio-Techne's innovative product portfolio to advance scientific research and healthcare in Turkey and Azerbaijan [3] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating approximately $1.2 billion in net sales in fiscal 2024 [4] - The company employs around 3,100 people worldwide and offers a vast portfolio of products that assist in scientific investigations and drug discovery [4]

Core Insights - BIO-key International, Inc. has entered into an agreement with Fiber Food Systems, Inc. to enhance security and operational efficiency in the food service sector through the integration of identity and access management (IAM) solutions [1][2][3] Company Overview - BIO-key specializes in workforce and customer identity and access management solutions, focusing on Identity-Bound Biometrics for secure authentication experiences [1][8] - Fiber Food Systems is dedicated to global food security and innovation in food technology, producing high-demand consumer packaged goods and plant-based proteins [1][9] Transaction Details - BIO-key acquired 5,000,000 shares of Boumarang, Inc. from Fiber in exchange for 595,000 shares of BIO-key, representing 19% of BIO-key's issued shares, strengthening its balance sheet with an additional $5 million in net assets [1] Strategic Collaboration - The partnership aims to combine BIO-key's IAM expertise with Fiber's food technology, enhancing security and streamlining access in high-traffic environments such as schools and universities [2][3] - BIO-key's PortalGuard IAM platform supports over 35 million users with phoneless, tokenless, and passwordless access options, which will be integrated into Fiber's food service operations [2][8] Innovation and Growth Opportunities - The collaboration is expected to improve operational efficiency in time-sensitive food service environments by deploying biometric authentication [4] - BIO-key's scalable IAM solutions will allow Fiber to implement tailored security measures across its expanding food tech and distribution network [5] - The partnership reflects a commitment to innovation in the food tech sector, setting a benchmark for safety and efficiency in food service technology [6] Leadership Statements - The CEO of BIO-key emphasized the importance of delivering secure IAM solutions to industries requiring seamless access, particularly in food services [7] - The Executive Chairperson of Fiber highlighted the alignment of their mission with BIO-key's technology to transform the food tech industry [7]

MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences ...

MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.Founded in 2020, Lead ...

MINNEAPOLIS, Nov. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership with ALZpath, Inc to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The collaboration leverages Bio-Techne's Ella™ fully automated, multiplexing immunoassay platform and ALZpath's proprietary pTau217 antibody to provide the Simple Plex Human Phospho-Tau (T217) ALZpath Assay. ALZpath The ALZpath pTau217 (phosphorylated Tau2 ...

Core Insights - BIO-key International, Inc. reported an 18% increase in Q3'24 revenues to $2.1 million, driven by a rise in license revenue from existing customers [2][3][7] - The company achieved a gross profit of $1.7 million with a gross margin of 78.3%, significantly improved from $0.3 million and 18.7% in Q3'23, due to higher license revenue and lower deployment costs [2][8] - The net loss for Q3'24 was reduced to $0.7 million from $1.8 million in Q3'23, reflecting improved revenue and stable operating expenses [2][10] Financial Highlights - Q3'24 revenues rose to $2.1 million from $1.8 million in Q3'23, with license revenue increasing by 52% to $1.4 million [2][7] - Gross profit improved to $1.7 million in Q3'24, compared to $0.3 million in Q3'23, primarily due to a higher proportion of high-margin license revenue [2][8] - Operating expenses were trimmed by $46,000 in Q3'24, reflecting proactive cost management [2][9] - Cash used in operating activities was $2.4 million for the first nine months of 2024, slightly higher than $2.3 million in the prior-year period [2] Recent Developments - The CEO highlighted strong demand from existing customers, with a notable order from a foreign financial services client for biometric identification technology [3][4] - The client has enrolled over 25 million customers using BIO-key technology and is upgrading to a "fingerprint only" solution, enhancing efficiency in customer identification [4][5] - The company plans to publish a whitepaper detailing the benefits of its biometric technology deployment [5] Balance Sheet and Cash Flow - As of September 30, 2024, current assets were approximately $4.6 million, including $1.8 million in cash, compared to $2.6 million at year-end 2023 [11][18] - The company raised $1.9 million in Q3'24 through a warrant inducement agreement, improving its cash position significantly [7][11] - Total liabilities increased to $6.3 million as of September 30, 2024, from $3.5 million at the end of 2023 [18][19]

Core Insights - Bio-Techne Corporation will showcase its latest research products at the AMP 2024 Annual Meeting & Expo, focusing on breast cancer monitoring and carrier screening [1][2] - The company aims to highlight new products that enhance data collection and analysis in molecular diagnostics [2] Product Presentations - The QuantideX® qPCR ESR1 exoMutation Kit will be featured, demonstrating analytical sensitivity of ≤0.1% across 11 ESR1 mutations [3] - The AmplideX® Nanopore Carrier Plus Kit will be presented, which combines PCR chemistry with Oxford Nanopore® technology to identify complex genetic alterations [4] Workshops and Discussions - A session on LDT compliance will address the challenges posed by the FDA's laboratory-developed test rule, discussing various tactical approaches for compliance [5] - Asuragen will host multiple activities and presentations throughout the event, including poster sessions on liquid biopsy surveillance and complex variant genotyping [6][7] Company Overview - Bio-Techne Corporation generated approximately $1.2 billion in net sales in fiscal 2024 and employs over 3,100 people globally [9]

R&D Systems Hematology Controls and Calibrators has completed the Class B Certification under the new European Union In Vitro Diagnostic RegulationThis press release updates the IVDR Classification to Class B from the prior Class C. MINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regul ...

R&D Systems Hematology Controls and Calibrators has completed the Class C Certification under the new European Union In Vitro Diagnostic RegulationMINNEAPOLIS, Nov. 11, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has recently achieved In Vitro Diagnostic Regulation (IVDR) certification for its R&D Systems Hematology Controls and Calibrators. This certification confirms that the products comply with the regulations and guidelines set forth by the European Union for in-vitro diagnostic devices. ...

Core Insights - Bio-Techne Corporation will present at multiple investor conferences in November 2024, including the UBS Global Healthcare Conference, Stifel 2024 Healthcare Conference, and Stephens NASH 2024 Conference [1] Company Overview - Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics [2] - The company generated approximately $1.2 billion in net sales in fiscal 2024 and employs around 3,100 people worldwide [2]